Imagine waiting for a lifesaving medication or vaccine only for it to arrive damaged after sitting in a hot shipping container for too long. Picture years of research and hard-earned grant funding being wasted because materials spoiled due to a delay on the tarmac. Though it isn’t always obvious, billions of people worldwide are affected by the inefficiencies of cold chain logistics.
Each year, the pharmaceutical industry alone spends approximately $18.6 billion on cold chain support to store and transport temperature-sensitive products. Losses related to cold chain failures add up to an additional $35 billion annually. Such costs are also challenging for universities, researchers, and reagent manufacturers.
But what if it was possible to stabilize fragile biomolecules without the use of freezing? Thanks to cutting-edge technology, it is.
Upkara is a diverse, forward-thinking biotechnology company headquartered in Ann Arbor, Michigan. It was founded by Pravansu Mohanty, Ph.D., as a spin-off of the Somnio think tank whose mission was to address global unmet needs. Upkara’s focus is biomolecule stabilization. Their novel technology, unlike the current stabilization technique of lyophilization or freeze drying, is rapid, cost-effective, and broadly applicable.